|indication=[[sinusitis|acute bacterial sinusitis]], [[bronchitis|acute bacterial exacerbation of chronic bronchitis]], [[community acquired pneumonia]], skin and skin structure infections: uncomplicated and complicated, complicated intra-abdominal infections
|indication=[[sinusitis|acute bacterial sinusitis]], [[bronchitis|acute bacterial exacerbation of chronic bronchitis]], [[community acquired pneumonia]], skin and skin structure infections: uncomplicated and complicated, complicated intra-abdominal infections
|hasBlackBoxWarning=Yes
|hasBlackBoxWarning=Yes
|adverseReactions=[[nausea]], [[diarrhea]], [[headache]], and [[dizziness]]
|adverseReactions=[[nausea]], [[diarrhea]], [[headache]], and [[dizziness]]
|blackBoxWarningTitle=WARNING: TENDON EFFECTS AND MYASTHENIA GRAVIS
|blackBoxWarningTitle=WARNING: TENDON EFFECTS AND MYASTHENIA GRAVIS
|blackBoxWarningBody=* Fluoroquinolones, including AVELOX®, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
|blackBoxWarningBody=* Fluoroquinolones, including AVELOX®, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
* Fluoroquinolones, including AVELOX, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid AVELOX in patients with known history of myasthenia gravis.
* Fluoroquinolones, including AVELOX, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid AVELOX in patients with known history of myasthenia gravis.
|fdaLIADAdult===Indications==
* For treating infections in adults ≥ 18 years of age caused by designated, susceptible bacteria.
:* Acute Bacterial Sinusitis
:*Acute Bacterial Exacerbation of Chronic Bronchitis
:*Community Acquired Pneumonia
:*Skin and Skin Structure Infections: Uncomplicated and Complicated
Complicated Intra-Abdominal Infections
==Dosage==
* The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.
[[File:Avelox injection table1.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
* Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with AVELOX IV may be switched to AVELOX Tablets when clinically indicated at the discretion of the physician.
'''AVELOX IV Solution for Infusion'''
* Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
* AVELOX IV should be administered by INTRAVENOUS infusion only. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.
* AVELOX IV should be administered by intravenous infusion over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place. Caution: rapid or bolus intravenous infusion must be avoided.
* Because only limited data are available on the compatibility of AVELOX intravenous injection with other intravenous substances, additives or other medications should not be added to AVELOX IV or infused simultaneously through the same intravenous line. If the same intravenous line or a Y-type line is used for sequential infusion of other drugs, or if the “piggyback” method of administration is used, the line should be flushed before and after infusion of AVELOX IV with an infusion solution compatible with AVELOX IV as well as with other drug(s) administered via this common line.
[[File:Avelox iv administration.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
'''Preparation for Administration of AVELOX IV'''
* To prepare AVELOX IV injection premix in flexible containers:
:*Close flow control clamp of administration set.
:*Remove cover from port at bottom of container.
:*Insert piercing pin from an appropriate transfer set (for example, one that does :*Not require excessive force, such as ISO compatible administration set) into port with a gentle twisting motion until pin is firmly seated.
'''NOTE''': Refer to complete directions that have been provided with the administration set.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
WARNING: TENDON EFFECTS AND MYASTHENIA GRAVIS
See full prescribing information for complete Boxed Warning.
* Fluoroquinolones, including AVELOX®, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
Fluoroquinolones, including AVELOX, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid AVELOX in patients with known history of myasthenia gravis.
For treating infections in adults ≥ 18 years of age caused by designated, susceptible bacteria.
Acute Bacterial Sinusitis
Acute Bacterial Exacerbation of Chronic Bronchitis
Community Acquired Pneumonia
Skin and Skin Structure Infections: Uncomplicated and Complicated
Complicated Intra-Abdominal Infections
Dosage
The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.
This image is provided by the National Library of Medicine.
Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with AVELOX IV may be switched to AVELOX Tablets when clinically indicated at the discretion of the physician.
AVELOX IV Solution for Infusion
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
AVELOX IV should be administered by INTRAVENOUS infusion only. It is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.
AVELOX IV should be administered by intravenous infusion over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place. Caution: rapid or bolus intravenous infusion must be avoided.
Because only limited data are available on the compatibility of AVELOX intravenous injection with other intravenous substances, additives or other medications should not be added to AVELOX IV or infused simultaneously through the same intravenous line. If the same intravenous line or a Y-type line is used for sequential infusion of other drugs, or if the “piggyback” method of administration is used, the line should be flushed before and after infusion of AVELOX IV with an infusion solution compatible with AVELOX IV as well as with other drug(s) administered via this common line.
This image is provided by the National Library of Medicine.
Preparation for Administration of AVELOX IV
To prepare AVELOX IV injection premix in flexible containers:
Close flow control clamp of administration set.
Remove cover from port at bottom of container.
Insert piercing pin from an appropriate transfer set (for example, one that does :*Not require excessive force, such as ISO compatible administration set) into port with a gentle twisting motion until pin is firmly seated.
NOTE: Refer to complete directions that have been provided with the administration set.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Moxifloxacin (injection) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Moxifloxacin (injection) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Moxifloxacin (injection) in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Moxifloxacin (injection) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Moxifloxacin (injection) in pediatric patients.
Contraindications
There is limited information regarding Moxifloxacin (injection) Contraindications in the drug label.
Warnings
WARNING: TENDON EFFECTS AND MYASTHENIA GRAVIS
See full prescribing information for complete Boxed Warning.
* Fluoroquinolones, including AVELOX®, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
Fluoroquinolones, including AVELOX, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid AVELOX in patients with known history of myasthenia gravis.
There is limited information regarding Moxifloxacin (injection) Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Moxifloxacin (injection) in the drug label.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Moxifloxacin (injection) in the drug label.
Drug Interactions
There is limited information regarding Moxifloxacin (injection) Drug Interactions in the drug label.